These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

490 related items for PubMed ID: 24992206

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients.
    Liu Y, Liu W, Li X, Xu Z, Wang X, Li C, Chen L, Xin S, Xu D.
    Antivir Ther; 2014; 19(6):551-8. PubMed ID: 24710668
    [Abstract] [Full Text] [Related]

  • 4. The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil.
    Liu Y, Li X, Xin S, Xu Z, Chen R, Yang J, Liu L, Wong VW, Yang D, Chan HL, Xu D.
    J Viral Hepat; 2015 Mar; 22(3):328-34. PubMed ID: 25132017
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
    Zhao L, Li X, Cheng Y, Chen R, Shao J, Zhou Y, Li Q, Liao H, Zhao Y, Liu L, Su H, Liu Y, Liu Y, Xu D.
    Antiviral Res; 2018 Jun; 154():26-34. PubMed ID: 29630974
    [Abstract] [Full Text] [Related]

  • 7. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
    Cha CK, Kwon HC, Cheong JY, Cho SW, Hong SP, Kim SO, Yoo WD.
    J Med Virol; 2009 Mar; 81(3):417-24. PubMed ID: 19152409
    [Abstract] [Full Text] [Related]

  • 8. Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
    Cho YK, Cui XJ, Jeong SU, Song BC.
    Antiviral Res; 2014 Dec; 112():8-17. PubMed ID: 25303802
    [Abstract] [Full Text] [Related]

  • 9. Monitoring of therapy in patients with chronic hepatitis B virus.
    Arrese E, Basaras M, Blanco S, Ruiz P, Cisterna R.
    Eur J Gastroenterol Hepatol; 2010 Jun; 22(6):736-40. PubMed ID: 19550344
    [Abstract] [Full Text] [Related]

  • 10. Increased occurrence of mutant rtI233V of HBV in patients receiving adefovir therapy.
    Liu Y, Xin S, Ye X, Chen R, Xu Z, Li X, Ye H, Cheng S, Xu D.
    Antivir Ther; 2016 Jun; 21(1):9-16. PubMed ID: 26079809
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.
    Inoue J, Ueno Y, Wakui Y, Niitsuma H, Fukushima K, Yamagiwa Y, Shiina M, Kondo Y, Kakazu E, Tamai K, Obara N, Iwasaki T, Shimosegawa T.
    J Viral Hepat; 2011 Mar; 18(3):206-15. PubMed ID: 20367795
    [Abstract] [Full Text] [Related]

  • 13. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
    Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouée-Durantel S, Villeneuve JP, Trépo C, Zoulim F.
    Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
    [Abstract] [Full Text] [Related]

  • 14. Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice.
    Liu Y, Zhou Y, Li X, Niu M, Chen R, Shao J, Si L, Luo D, Lin Y, Li L, Zhang K, Xiao X, Xu Z, Liu M, Lu M, Zoulim F, Xu D.
    Emerg Microbes Infect; 2019 Jun; 8(1):354-365. PubMed ID: 30866789
    [Abstract] [Full Text] [Related]

  • 15. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2).
    Osiowy C, Villeneuve JP, Heathcote EJ, Giles E, Borlang J.
    J Clin Microbiol; 2006 Jun; 44(6):1994-7. PubMed ID: 16757589
    [Abstract] [Full Text] [Related]

  • 16. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V.
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Detection of resistance mutations in chronic hepatitis B patients receiving antiviral therapy for over one year].
    Aydoğan S, Ergünay K, Balaban Y, Alp A, Simşek H, Tatar G, Hasçelik G, Us D.
    Mikrobiyol Bul; 2013 Jul; 47(3):472-81. PubMed ID: 23971924
    [Abstract] [Full Text] [Related]

  • 19. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
    Zaaijer HL, Takkenberg RB, Weegink CJ, Rebers SP, Menting S, Reesink HW, Schinkel J, Molenkamp R.
    J Med Virol; 2009 Mar; 81(3):413-6. PubMed ID: 19152408
    [Abstract] [Full Text] [Related]

  • 20. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.
    Choe WH, Hong SP, Kim BK, Ko SY, Jung YK, Kim JH, Yeon JE, Byun KS, Kim KH, Ji SI, Kim SO, Lee CH, Kwon SY.
    Antivir Ther; 2009 Mar; 14(7):985-93. PubMed ID: 19918102
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.